"10.1371_journal.pone.0113701","plos one","2014-11-21T00:00:00Z","Alexander Tschulakow; Sarah Christner; Sylvie Julien; Maximilian Ludinsky; Markus van der Giet; Ulrich Schraermeyer","Section of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, Tuebingen, Germany; STZ OcuTox Preclinical Drug Assessment, Hechingen, Germany; Division of Nephrology, Charité University Medicine, Charité Campus Benjamin Franklin, Berlin, Germany","Conceived and designed the experiments: SJ US. Performed the experiments: AT SC. Analyzed the data: AT SC SJ ML MG US. Contributed reagents/materials/analysis tools: US. Wrote the paper: AT SC SJ.","This study was financially supported by Novartis Pharma AG. Ranibizumab is marketed by Novartis and Ulrich Schraermeyer is a consultant on ocular toxicity to Novartis Pharma AG. SZT Ocutox is a Steinbeis transfer centre. Ulrich Schraermeyer and Sylvie Julien work as freelancers for STZ OcuTox, and Ulrich Schraermeyer is the managing director. The Steinbeis Foundation is an institute headquartered in Stuttgart, Germany dedicated to the transfer of academic findings and knowledge into the field of business. The transfer centres operate as standalone profit centres. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","11","Alexander Tschulakow","AT",6,TRUE,2,2,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
